Related Experiment Video
Updated: Apr 14, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory
A Wree1, C D Johnson1, J Font-Burgada2
1Department of Pediatrics, University of California-San Diego, La Jolla, CA, USA.
Abstract:
Liver cancer is a major health-care concern and its oncogenic mechanisms are still largely unclear. Persistent hepatocyte cell death is a common feature among various chronic liver diseases, the blocking of which presents as logical treatment. Therefore, we aimed at investigating tumor development in mice with hepatocyte-specific Bid depletion--a BH3-only Bcl-2 family member that amplifies apoptotic death signals. Hepatocyte-specific conditional Bid-knockout mice (Bid(Δhep)) were injected with 25 mg/kg diethylnitrosamine (DEN) at 14 days of age, and liver tumorigenesis was investigated 9 months later. Additionally, different models of acute liver injury were used including: acute high-dose DEN challenge, 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet and carbon tetrachloride (CCL4) injection. Bid(Δhep) mice developed significantly fewer tumors, showed smaller maximal and average tumor size and reduced tumor incidence. In the acute DEN model, 48 h post injection we observed a significant reduction in liver injury in Bid(Δhep) animals, assessed via serum transaminases and liver histopathology. Furthermore, TNF-α, IL-1ß, cJUN and IL-6 mRNA expression was reduced. These findings were accompanied by reduced compensatory hepatocyte proliferation in Bid(Δhep) mice when compared with controls by immunohistochemistry for Ki67 and proliferating cell nuclear antigen 48 h after DEN injection. In the acute CCL4 model, Bid(Δhep) mice displayed reductions in liver injury and inflammation when compared with controls. No differences in liver injury and serum bilirubin levels were detected in Bid(Δhep) and Bid(flo/flo) mice fed with DDC, which induces bile duct injury and a ductular reaction. Our study demonstrates that in DEN-induced hepatocellular carcinoma, the inhibition of hepatocyte death pathways through Bid deletion protects animals from tumorigenesis. These results suggest that reducing hepatocyte cell death, liver inflammation and compensatory proliferation has a stronger beneficial effect than the potential side effect of enhancing tumor cell survival.
Insights
Blocking hepatocyte cell death by depleting Bid reduces liver cancer development and injury. This inhibition also decreases inflammation and compensatory proliferation, suggesting a therapeutic benefit in hepatocellular carcinoma.
Area of Science:
- Hepatology
- Oncology
- Molecular Biology
Background:
- Liver cancer is a significant health concern with unclear oncogenic mechanisms.
- Persistent hepatocyte cell death is common in chronic liver diseases, making its blockade a potential treatment strategy.
Purpose of the Study:
- To investigate the role of Bid, a key mediator of apoptotic death signals, in liver tumorigenesis.
- To evaluate the impact of hepatocyte-specific Bid depletion on diethylnitrosamine (DEN)-induced liver cancer and acute liver injury models.
Main Methods:
- Hepatocyte-specific conditional Bid-knockout mice (Bid(Δhep)) were used.
- Mice were injected with DEN to induce liver tumors and subjected to acute liver injury models (DEN, DDC diet, CCl4).
- Tumor development, liver injury markers, inflammatory gene expression, and cell proliferation were assessed.
Main Results:
- Bid(Δhep) mice exhibited significantly reduced tumor incidence, size, and number after DEN injection.
- Bid deletion lessened liver injury, inflammation (reduced TNF-α, IL-1ß, IL-6, cJUN), and compensatory hepatocyte proliferation in acute DEN and CCl4 models.
- No significant differences in liver injury were observed in the DDC diet model.
Conclusions:
- Inhibition of hepatocyte death pathways by Bid deletion protects against DEN-induced hepatocellular carcinoma.
- Reducing hepatocyte cell death, inflammation, and compensatory proliferation offers a beneficial therapeutic strategy for liver cancer.
